OCSiAl opens first European plant
OCSiAl has opened its first European graphene nanotubes facility in Serbia. It will produce 60 tonnes/year under the Tuball band and the company plans to double this by launching a second synthesis unit within the next year. The modular design means it is able to scale production rapidly.
The 10,000 m2 plant includes a nanotube synthesis unit, dispersion and concentrate production lines, a research hub and quality control laboratories. The dispersion line can produce enough material for more than 4 million electric vehicles, while the concentrate line will supply nanotubes for conductive and enhanced composites and coatings.
RELATED ARTICLES
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
Posco Future M has conducted the initial shipment of products from its 30,000 tonnes/year nickel-cobalt-aluminium (NCA) cathode material plant in Pohang, South Korea.
Mining giant Rio Tinto has agreed to acquire Arcadium Lithium, the company created by the merger of Livent and Allkem in January, for $5.85/share, which represents a 90% premium to Arcadium’s share price before the deal was announced. The offer values the firm at about $6.7 billion.
Chemours has opened Chemours Battery Innovation Centre (CBIC) at the Chemours Discovery Hub in Newark, Delaware. CBIC will support the testing and scaling of next-generation lithium-ion battery technologies to produce batteries for hybrid and electric vehicles.
Arcadium Lithium, the company formed by the merger of Livent and Allkem at the start of the year, has acquired the lithium metal business of Li-Metal for $11 million. This includes a pilot production facility in Ontario.
Merck KGaA is to sell its global Surface Solutions business unit to Global New Material International Holdings (GNMI), one of the world’s largest pearlescent pigment producers, for €665 million in cash, subject to regulatory approvals and other customary closing conditions.
